Nuvig Therapeutics

aid: nuvig-therapeutics
name: Nuvig Therapeutics
description: 'Nuvig Therapeutics, Inc. is a privately held, clinical-stage biotechnology company headquartered at 3450 Hillview
  Avenue, Palo Alto, California, developing next-generation immunomodulators for chronic autoimmune and inflammatory disease.
  Its lead investigational candidate, NVG-2089, is an engineered Fc fragment designed to selectively engage type II Fc receptors
  and harness an endogenous regulatory mechanism that resolves autoimmune dysregulation while preserving normal immune function;
  the first patient was dosed in a Phase 2 trial in chronic inflammatory demyelinating polyneuropathy (CIDP) in May 2025.
  The company announced a $161 million Series B financing in December 2024. Nuvig is a therapeutics developer, not a software
  vendor: as of August 2026 it publishes no developer portal, API reference, SDK, GitHub organization, or machine-readable
  API contract of any kind. Its public web surface is a corporate WordPress site covering science, pipeline, team, news and
  careers, from which the only machine-readable artifact published is a Yoast-generated llms.txt.'
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: false
  label: Hosted service · you call their endpoint
  confidence: medium
  source:
  - pricing
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
image: https://nuvigtx.com/wp-content/uploads/2022/04/bg-logo-nuvig.svg
url: https://raw.githubusercontent.com/api-evangelist/nuvig-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profile
x-tier-reason: enrichment-pass
specificationVersion: '0.23'
x-enrichment:
  date: '2026-08-04'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Nuvig is a clinical-stage biotech whose product is a drug candidate (NVG-2089), not software — nuvigtx.com is a
    five-page corporate WordPress site with no /developers, /api or /docs path, no GitHub organization, and no package on
    any registry.
  evidence:
  - url: https://nuvigtx.com/developers
    status: 404
  - url: https://nuvigtx.com/openapi.json
    status: 404
  - url: https://nuvigtx.com/.well-known/agent-card.json
    status: 404
  - url: https://nuvigtx.com/llms.txt
    status: 200
  checked: '2026-08-04'
created: '2026-08-04'
modified: '2026-08-04'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Immunology
- Autoimmune Disease
- Therapeutics
- Clinical Trials
- Life Sciences
- United States
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/nuvig-therapeutics-domain-security.yml
- type: Website
  url: https://nuvigtx.com/
- type: About
  url: https://nuvigtx.com/science/
- type: Science
  url: https://nuvigtx.com/science/
- type: Pipeline
  url: https://nuvigtx.com/pipeline/
- type: Team
  url: https://nuvigtx.com/team/
- type: News
  url: https://nuvigtx.com/news/
- type: Blog
  url: https://nuvigtx.com/news/
- type: BlogFeeds
  url: https://nuvigtx.com/feed/
- type: Careers
  url: https://nuvigtx.com/careers/
- type: Contact
  url: https://nuvigtx.com/contact/
- type: TermsOfService
  url: https://nuvigtx.com/terms-of-use/
- type: PrivacyPolicy
  url: https://nuvigtx.com/privacy-policy/
- type: CookiePolicy
  url: https://nuvigtx.com/cookie-policy/
- type: LinkedIn
  url: https://www.linkedin.com/company/nuvig-therapeutics-inc
- type: Twitter
  url: https://x.com/nuvigtx
- type: Investors
  url: https://www.hiive.com/securities/nuvig-therapeutics-stock
- type: LLMsTxt
  url: llms/nuvig-therapeutics-llms.txt